The combination of strong organic growth, successful M&A integration, and raised guidance suggests Strata is executing well on its platform strategy. Traders should monitor whether Adjusted EBITDA margin expansion (7.1% in 2025, up from 2.6%) can be sustained and whether free cash flow improves from current negative levels. The undrawn $30M credit facility provides optionality for further acquisitions.
Price Chart
Executive Summary
Strata Critical Medical (SRTA) reported strong Q4 and full-year 2025 results, with revenue up 83.5% YoY to $66.8 million in Q4 and full-year revenue of $197.1 million, beating guidance. Adjusted EBITDA surged 274.5% to $14.1 million for the year. The company raised its 2026 revenue and Adjusted EBITDA guidance ranges, citing strong organic growth and integration of the Keystone acquisition. Despite a quarterly net loss, non-GAAP metrics show accelerating profitability and operational leverage.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $66.8 million, up 83.5% YoY
- Full-year 2025 revenue: $197.1 million, up 34.3% YoY, above guidance high end
- Full-year 2025 Adjusted EBITDA: $14.1 million, up 274.5% YoY
- Q4 2025 Adjusted EBITDA: $7.0 million, up 547% YoY
- Logistics segment organic revenue grew 35.3% YoY in Q4
- Raised 2026 revenue guidance to $260–275 million (from $255–270M)
- Raised 2026 Adjusted EBITDA guidance to $29–33 million (from $28–32M)
- Closed $30M asset-backed credit facility with JPMorgan, undrawn
Financial Impact
Revenue grew $50.3 million YoY in 2025, with Adjusted EBITDA improving by $10.3 million. 2026 revenue guidance implies 32% median growth over 2025.
Risk Factors
- GAAP net loss from continuing operations was $20.1 million in 2025
- Operating cash flow was negative $8.3 million in Q4, driven by working capital and non-recurring items
- Free cash flow before aircraft acquisitions was negative $8.7 million in Q4
- Forward guidance not reconciled to GAAP, with key variables like stock-based compensation excluded
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248187 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | Press Release | $4.66 | awaiting T+1 | — | $4.76 (+2.15%) |
Oct 15, 2026 11d ago | SC 13D | $4.54 $4.54 | · 0.00% | ▼ −0.42% | $4.76 (+4.85%) |
Oct 2, 2026 25d ago | 144 | $4.73 $4.81 | ▲ +1.69% | ▲ +1.02% | $4.76 (+0.63%) |
Aug 21, 2026 9w ago | Institutional Cluster | $6.24 $5.97 | ▼ −4.33% | ▼ −4.03% | $4.76 (−23.72%) |
Aug 4, 2026 12w ago | 8-K | $5.57 $5.85 | ▲ +5.03% | ▲ +5.23% | $4.76 (−14.54%) |
Jul 21, 2026 13w ago | Press Release | $5.08 $5.09 | ▲ +0.20% | ▲ +1.43% | $4.76 (−6.30%) |
Jun 10, 2026 19w ago | Insider Cluster | $5.49 $5.43 | ▲ +1.09% | ▲ +1.63% | $4.76 (+13.30%) |
May 7, 2026 24w ago | Press Release | $5.57 $5.66 | ▲ +1.62% | ▲ +1.38% | $4.76 (−14.54%) |
Mar 3, 2026 34w ago | Press Release | $4.80 $4.89 | ▲ +1.88% | ▲ +1.11% | $4.76 (−0.83%) |
Feb 28, 2026 34w ago | Institutional Cluster | $4.49 $4.80 | ▲ +6.90% | ▲ +7.82% | $4.76 (+6.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers